Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Clozapine 20 mg/mL in Ora-Sweet and Ora-Plus

Author(s):  Allen Loyd V Jr

Issue:  Jan/Feb 2023 - Volume 27, Number 1
View All Articles in Issue

Page(s):  51

Clozapine 20 mg/mL in Ora-Sweet and Ora-Plus Page 1

Download in electronic PDF format for $65

Abstract:  A formulation for preparing Clozapine 20 mg/mL in Ora-Sweet and Ora-Plus. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords: Loyd V. Allen, Jr., PhD, RPh, clozapine, formulation, schizophrenia, psychosis, atypical antipsychotic agent, tricyclic dibenzodiazepine derivative, oral suspensions

Related Categories: EXCIPIENTS, FORMULATIONS, MENTAL HEALTH, DOSAGE FORMS/DRUG CARRIERS, NEUROLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Clozapine 20 mg/mL in Ora-Sweet and Ora-Plus
Allen Loyd V Jr
Jan/Feb 2023
Pg. 51

Rapid-Dissolve Technology: An Interview With Loyd V. Allen, Jr., PhD, RPh
Allen Loyd V Jr
Nov/Dec 2003
Pg. 449-450

Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
Jul/Aug 2001
Pg. 310-312

Clozapine 20-mg/mL Oral Suspension
Allen Loyd V Jr
May/Jun 2010
Pg. 243

Aripiprazole 1 mg/mL in Oral-Plus:Ora-Sweet (1:1) Oral Suspension
Allen Loyd V Jr
Jul/Aug 2019
Pg. 314

Quetiapine Fumarate 10 mg/mL in Ora-Blend
Allen Loyd V Jr
Nov/Dec 2021
Pg. 506

Haloperidol 0.5-mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
Sep/Oct 2021
Pg. 417

Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Pramann Lance A
, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
May/Jun 2016
Pg. 257-261

Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Jan/Feb 2020
Pg. 60

Penfluridol, a Unique Psychiatric Medicine for the Treatment of Chronic Schizophrenia
Zur Eyal
Mar/Apr 2019
Pg. 113-119